Formoterol (foradil) in treatment of chronic obstructive pulmonary disease by evidence-based medicine

1. Benhamou D., Cavelier V., Muir J.F. et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil® Aerolizer™) with salbutamol (Ventodisk).Respir. Med. 2001; 95 (10). Web site: w w w .m dconsult.com .

2. Dahl R., Greefhorst A.P.M ., Nowak D. et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 778-784.

3. Global initiative for chronic obstructive lung disease. National Heart, Lung, and Blood Institute. Publication Number 2701. March 2001.

4. Lotvall J. Pharmacological similarities and differences between beta2-agonists. Respir. Med. 2001; 95 (suppl.B). Web site: w ww.m dconsult.com

5. Mario Cazzola М., Centanni S., Regorda C. et al. Onset of action of single doses of formoterol administered via turbuhaler in patients with stable COPD. Pulmon. Pharmacol. Ther. 2001; 14 (1). Web site: www.mdconsult.com.

6. Mosby's Drug Consult. Mosby's GenRx®, 2002, 12th ed. Версия для Internet. Web site: www.mdconsult.com.

7. Rossi A., Kristufek P., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 212 (4). Web site: www.mdconsult.com